Literature DB >> 29427756

CRISPR/CAS9 ablation of individual miRNAs from a miRNA family reveals their individual efficacies for regulating cardiac differentiation.

Ziyao Zhang1, Rebecca Ursin1, Samiksha Mahapatra1, G Ian Gallicano2.   

Abstract

Although it is well understood that genetic mutations, chromosomal abnormalities, and epigenetic miscues can cause congenital birth defects, many defects are still labeled idiopathic, meaning their origin is not yet understood. microRNAs are quickly entering the causal fray of developmental defects. miRNAs use a 7-8 base-pair seed sequence to target a corresponding sequence on one or multiple mRNAs resulting in rapid down-regulation of translation. miRNAs can also control protein 'amounts' in cells. As a result if miRNAs are over or under expressed during development protein homeostasis can be compromised resulting in defects in the development of organ systems. Here, we show that during differentiation of embryonic stem cells, individual miRNAs that reside in the miRNA17 family (composed of 14 miRNAs) do not share the same function even though they have the same seed sequence. The advent of CRISPR/CAS9 technology has not only yielded a true observation of individual miRNA function, it has also reconnected advanced molecular biology approaches to classical cell biology approaches such as gene rescue. We show that miRNA106a and to a lesser extent miR17 and 93 target the cardiac suppressor gene Fog2, which specifically suppress Gata-4 and Coup-TF2. However, when each miRNA is knocked out, we find that their targeting efficacies for Fog2 differ resulting in varying degrees of cardiac differentiation.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29427756     DOI: 10.1016/j.mod.2018.02.002

Source DB:  PubMed          Journal:  Mech Dev        ISSN: 0925-4773            Impact factor:   1.882


  6 in total

Review 1.  microRNAs and cardiac stem cells in heart development and disease.

Authors:  Bo Li; Xianmei Meng; Lubo Zhang
Journal:  Drug Discov Today       Date:  2018-05-28       Impact factor: 7.851

Review 2.  Recent insights into the microRNA and long non-coding RNA-mediated regulation of stem cell populations.

Authors:  Carolina Estrada-Meza; Andrea Torres-Copado; Luisa Loreti González-Melgoza; Luis M Ruiz-Manriquez; Marcos De Donato; Ashutosh Sharma; Surajit Pathak; Antara Banerjee; Sujay Paul
Journal:  3 Biotech       Date:  2022-09-10       Impact factor: 2.893

Review 3.  The MicroRNA Family Both in Normal Development and in Different Diseases: The miR-17-92 Cluster.

Authors:  Xiaodan Bai; Shengyu Hua; Junping Zhang; Shixin Xu
Journal:  Biomed Res Int       Date:  2019-02-03       Impact factor: 3.411

4.  CRISPRi for specific inhibition of miRNA clusters and miRNAs with high sequence homology.

Authors:  Monika Drobna-Śledzińska; Natalia Maćkowska-Maślak; Roman Jaksik; Paulina Dąbek; Michał Witt; Małgorzata Dawidowska
Journal:  Sci Rep       Date:  2022-04-15       Impact factor: 4.996

5.  Reversing Cardiac Hypertrophy at the Source Using a Cardiac Targeting Peptide Linked to miRNA106a: Targeting Genes That Cause Cardiac Hypertrophy.

Authors:  G Ian Gallicano; Jiayu Fu; Samiksha Mahapatra; Michael V R Sharma; Conor Dillon; Claire Deng; Maliha Zahid
Journal:  Pharmaceuticals (Basel)       Date:  2022-07-15

Review 6.  A glance at the application of CRISPR/Cas9 gene-editing technology in cardiovascular diseases.

Authors:  Neda Roshanravan; Helda Tutunchi; Farzad Najafipour; Mohammadreza Dastouri; Samad Ghaffari; Alireza Jebeli
Journal:  J Cardiovasc Thorac Res       Date:  2022-06-14
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.